Skip page top navigation FDA Logo--links to FDA home
page Logo of and Link to start page of Office of Regulatory Affairs, 
U.S. Food and Drug Administration U.S. Food and Drug Administration Office of Regulatory Affairs HHS Logo and link to Department of Health and Human Services website

FDA Home Page | Federal-State | Import Program | Compliance | Inspection | Science | ORA Search

IA#60-01 --- 2/24/87


BACKGROUND

Minneapolis and Detroit districts recently reported activity in the
importation of Canadian Tagamet.  Detroit district refused entry of a shipment
of Canadian Tagamet which was consigned to Crosstown Drug, Hamlake, Minnesota.

We were previously aware that shipments had entered through Portland, Oregon
and Murfreesboro, Tennessee, while Buffalo, Boston, and Nashville districts
had previously detained attempted entries.  There is reason to believe that
there may be attempts to enter Canadian Tagamet through other U.S. ports of
entry as well.

Smith, Kline & French Laboratories (USA) is concerned about such illegal
importations and they are making every effort to stop them.  Smith, Kline &
French, Canada Ltd., has not been implicated in the illegal importation.  Two
shippers that have been identified, Speedway Drugs, Edmonton, Alberta, Canada,
and National Drug Ltd., Winnipeg, Manitoba, Canada, (shipper of product to
Crosstown Drug) are wholesalers who do not purchase directly from the
manufacturer, but from other wholesalers.

Tagamet manufactured in Canada, is considered a new drug which may only be
imported/marketed in this country pursuant to an approved new drug application
(NDA).  No such approval has been granted, nor is any application for approval
on file for the Canadian facility.

The unapproved product is produced by:

    Smith, Kline & French, Canada Ltd.
    1940 Argentina Road
    Mississauga (Toronto) Ontario

The identifying features of the package are:

1)  Generally packed in bottles of 1000 tablets:

2)  The name of the manufacturer, Smith, Kline & French, Canada Ltd., and
    directions for use appear on the label in English and French;

3)  The label fails to bear a NDC number, nor is there an insert attached to
    the package:

4)  The label bears a number required by the Canadian Government, known as a
    DIN number, which for Tagamet 300 mg tablet is DIN #397474:

5)  Tagamet (Canadian) is the same color, size, and shape as the American
   version, but the tablet markings are different as follows:

              American Tagamet                      Canadian Tagamet

              Tagamet 300                           SKF
              SKF                                   T13

              Tagamet 200                           SKF
              SKF                                   T12

While we have no information that there is any effort to import generic
cimetidine manufactured in Canada, you should be aware that there are three
Canadian manufacturers for the generic drug product, two of which have the
same light green color as the American product.  However, because of
significant price differential, an attempt may be made to import the generic
product.  We therefore, include the following information for your records.

                                 Available
 Manufacturer    Product Name    Strength           Tablet Markings

                                               All strengths light green color
Apotex, Inc.     APO-Cimetidine   300 mg       Marked APO 300
406 Ormont Dr.   Tablet           200 mg       Marked APO 200

                                               All strengths light green color
NovoPharm        Nova Cimetidine  300 mg       Marked NOVO 300
1290 Ellsmere    Tablet           200 mg       Marked NOVO 200
Rd. Scarborough
Toronto, Canada

Horner Labs Ltd. Pettol Tablet    300 mg       300 mg - blue color
5485 Ferrier St.                               Marked FWH
Montreal, Canada                                      300

                                  200 mg       200 mg - yellow color
                                               Marked FWH
                                                      200

GUIDANCE:

Increased surveillance is indicated for SKF's Tagamet Tablets (all strengths)
and Cimetidine Tablets (all strengths) produced in Canada.  If they are
encountered, detain, charging:

     "The article is violative within the meaning of section 801(a) (3)
      of the Federal Food, Drug, and Cosmetic Act in that it appears to
      be a new drug without an approved new drug application (NDA)
      pursuant to section 505."